CHMP backs two AstraZeneca drugs: Klygefa in gMG, Enhertu in early breast cancerSep 21Regulatory milestoneAstraZenecafam-trastuzumab deruxtecan-nxki
EU clears Enhertu plus pertuzumab as first-line HER2-positive metastatic breast cancer therapyAug 31Regulatory decisionAstraZenecafam-trastuzumab deruxtecan-nxki
BeyondSpring updates Plinabulin data, names new CEO, reports Q2 2026 resultsAug 14Quarterly updateBeyondSpring Pharmaceuticals Inc.
ALX Oncology posts Q2 2026 results, reaffirms mid-2027 ASPEN-09-Breast readoutAug 6Quarterly updateALX Oncology Inc.
AstraZeneca posts NATRON Phase III benralizumab results; registers ROSY-S anifrolumab rollover studyJul 10Weekly roundup, 9 itemsanifrolumab-fniaAstraZeneca
Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular eventsJul 10Weekly roundup, 8 itemsAstraZenecabaricitinib
EU approves Enhertu as first tumor-agnostic HER2-directed ADCJun 29Regulatory decisionAstraZenecafam-trastuzumab deruxtecan-nxki
Sign inSign in